Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Concentra Biosciences Continues Biotech Acquisition Spree with Elevation Oncology Deal

Concentra Biosciences, a vehicle controlled by hedge fund Tang Capital Partners, has agreed to acquire Elevation Oncology for $0.36 per share in cash. The deal, which has received full support from Elevation's board, marks the latest in a series of acquisitions by Concentra targeting struggling biotech companies.

NoahAI News6/10/2025

NewAmsterdam's Cholesterol Drug Shows Promise in Alzheimer's Prevention

NewAmsterdam Pharma's experimental cholesterol-lowering drug, obicetrapib, has demonstrated potential in combating Alzheimer's disease, according to recent clinical trial results. This development marks a significant step forward in the pursuit of preventative therapies for neurodegenerative disorders and highlights the growing intersection between cardiovascular and neurological research.

NoahAI News6/10/2025

Avidity's Muscular Dystrophy Drug Shows Promise, FDA Open to Accelerated Approval

Avidity Biosciences has made significant strides in the treatment of facioscapulohumeral muscular dystrophy (FSHD), with its novel drug delpacibart braxlosiran showing promising results in early-stage trials. The San Diego-based biotech company announced on Monday that the U.S. Food and Drug Administration (FDA) is open to receiving an application for accelerated approval of the drug, potentially paving the way for the first disease-modifying treatment for FSHD.

NoahAI News6/10/2025

CDC's Advisory Committee on Immunization Practices in Turmoil Amid Vaccine Policy Shifts

The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) is facing significant upheaval following a series of controversial decisions and personnel changes. These developments have raised concerns about the future of vaccine policy in the United States and the potential influence of newly appointed Health and Human Services (HHS) Secretary Robert F. Kennedy Jr.

NoahAI News6/10/2025

Keros Therapeutics to Return $375M to Investors Amid Strategic Shift

Keros Therapeutics, a Massachusetts-based biotech company, has announced plans to return $375 million to investors following a period of shareholder activism and a significant safety signal in one of its clinical programs. This decision comes as part of a broader strategic review and restructuring effort aimed at refocusing the company's pipeline and addressing investor concerns.

NoahAI News6/10/2025

Merck's Oral PCSK9 Inhibitor Shows Promise in Phase III Trials, Positioning Company as Leader in Cholesterol Treatment Race

Merck & Co. has taken a significant step forward in its bid to bring the first oral PCSK9 inhibitor to market, with its experimental drug enlicitide decanoate showing positive results in two Phase III trials. The studies, part of the company's CORALreef program, demonstrated the drug's ability to significantly lower low-density lipoprotein cholesterol (LDL-C) in patients with high cholesterol, potentially unlocking a multi-billion dollar opportunity for the pharmaceutical giant.

NoahAI News6/10/2025

Metsera's Amylin-Targeting Obesity Drug Shows Promise in Early Trial

Metsera, a rising star in the biotech industry, has reported encouraging results from a Phase I clinical trial of its novel obesity treatment, MET-233i. The experimental drug, which targets the hormone amylin, demonstrated significant weight loss potential and a favorable dosing profile that could position it as a strong competitor in the rapidly evolving weight loss medication market.

NoahAI News6/10/2025

FDA Refuses to Review Axsome's Fibromyalgia Drug, Company Plans New Trial

Axsome Therapeutics has encountered a significant setback in its efforts to bring esreboxetine, a potential treatment for fibromyalgia, to market. The U.S. Food and Drug Administration (FDA) has refused to review the company's new drug application (NDA) for the asset, citing concerns over one of the two trials included in the filing.

NoahAI News6/10/2025

Abcuro Bolsters Commercial Team with Industry Veteran Ahead of Potential Drug Launch

Abcuro, a Massachusetts-based biotech company, has taken a significant step towards commercialization by appointing Courtney Cupples as its new Chief Commercial Officer. This strategic move comes as the company prepares for the potential launch of its inflammatory disease drug, ulviprubart.

NoahAI News6/10/2025

FDA Clears Reflow Medical's Innovative Retrievable Stent System for Below-the-Knee Treatment

Reflow Medical has achieved a significant milestone with the FDA's de novo clearance of its novel retrievable stent system, designed to improve blood flow in blocked arteries below the knee while leaving no permanent implant behind. This groundbreaking device offers new hope for patients suffering from infrapopliteal arterial disease and chronic limb-threatening ischemia.

NoahAI News6/10/2025

Sanofi Ramps Up Beyfortus Production Amid Looming Competition in RSV Market

Sanofi has announced an ambitious supply plan for its respiratory syncytial virus (RSV) antibody, Beyfortus, developed in partnership with AstraZeneca. The company aims to begin shipping the product early in the third quarter, with current supply levels already matching the total doses distributed last year. This move comes just one day before the potential FDA approval of a rival RSV monoclonal antibody from Merck & Co.

NoahAI News6/10/2025

George Medicines Receives FDA Approval for Triple-Combo Hypertension Pill

In a significant development for hypertension treatment, the U.S. Food and Drug Administration (FDA) has approved George Medicines' Widaplik, a novel triple-combination pill for the initial treatment of high blood pressure. This approval marks a new era in hypertension management, offering patients a simplified approach to achieving blood pressure control.

NoahAI News6/10/2025

«1...51 52 53...67 »